Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib
11 juin 2021 09h00 HE
|
Constellation Pharmaceuticals , Inc.
Translational data support the disease-modifying potential of pelabresibCentral pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib...
Constellation Pharmaceuticals to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
19 févr. 2021 16h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results
18 févr. 2021 10h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise
12 juin 2020 02h30 HE
|
Constellation Pharmaceuticals , Inc.
Spleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated from standard of careSpleen responses demonstrated in...
Constellation Pharmaceuticals to Participate in Investor Conference
29 mai 2020 09h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610
28 mai 2020 12h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Provides Update of Preliminary Data for CPI-0610 in Three EHA Abstracts
14 mai 2020 08h00 HE
|
Constellation Pharmaceuticals , Inc.
Continued high rate of SVR35 in 1L patients: 72% at 12 weeks and 67% at 24 weeksSVR35 responses and transfusion dependence conversion observed in 2L monotherapy patients Improvement in bone marrow...
Constellation Pharmaceuticals Announces First-Quarter 2020 Financial Results
06 mai 2020 07h00 HE
|
Constellation Pharmaceuticals , Inc.
EHA abstracts to publish on May 14 with an interim update across the MANIFEST trial cohortsConstellation to provide an additional interim update from MANIFEST at EHA in mid-June Company continues to...
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results
10 mars 2020 16h12 HE
|
Constellation Pharmaceuticals , Inc.
Clinical data presented at 2019 American Society of Hematology (ASH) annual meeting suggested that CPI-0610 could offer meaningful benefits beyond standard of care in myelofibrosis In addition to...
Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2019 Results
06 mars 2020 13h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...